Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806421 | 0.89 | HSP90AA1 (0.49) | HSP90AA1MAPTPOLBHSP90AB1ALDH1A1 | |
| SCHEMBL2809323 | 0.85 | HSP90AA1 (0.52) | HSP90AA1MAPTPOLBHSP90AB1ALDH1A1 | |
| SCHEMBL2806325 | 0.82 | MAPT (0.69) | HSP90AA1MAPTTP53LMNAPOLB | |
| SCHEMBL8203169 | 0.77 | KDM4E (0.48) | MAPTTP53HTR3AHRH4USP2 | |
| SCHEMBL8203715 | 0.75 | HTR3A (0.48) | HSP90AA1HTR3AHRH4ALDH1A1 | |
| SCHEMBL24920528 | 0.75 | LMNA (0.61) | HSP90AA1MAPTTP53LMNAPOLB | |
| SCHEMBL28516998 | 0.75 | MAPT (0.52) | HSP90AA1MAPTTP53LMNAPOLB | |
| SCHEMBL30405241 | 0.75 | MAPT (0.52) | HSP90AA1MAPTTP53LMNAPOLB | |
| SCHEMBL17624369 | 0.74 | LMNA (0.47) | HSP90AA1MAPTTP53LMNAPOLB | |
| SCHEMBL8207690 | 0.74 | HSP90AA1 (0.43) | HSP90AA1POLBHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| CN-101663284-A | Macrocyclic compounds as hcv ns3 protease inhibitors | NOVARTIS AG | 2010-03-03 | — | — | CN | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | HSP90AA1 2838/4885MAPT 4041/4885TP53 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.